Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPRC | P08575 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | MMP3 | P08254 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 3/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.34 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.34 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.34 |
| ▸ | CSNK2A1 | P68400 | 4/20 | 0.33 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29392470 | 1.00 | PTPRC (0.41) | PTPRCPTPN1ENPP2CYP11B1CYP11B2 | |
| SCHEMBL333000 | 0.84 | CYP1A2 (0.44) | PTPRCPTPN1ENPP2CYP11B1CYP11B2 | |
| SCHEMBL7198498 | 0.81 | ENPP2 (0.41) | PTPRCPTPN1ENPP2KDM4ETDP1 | |
| SCHEMBL435376 | 0.81 | HTT (0.41) | PTPRCPTPN1ENPP2CYP11B1CYP11B2 | |
| SCHEMBL19899969 | 0.81 | MEN1 (0.52) | KDM1AKCNH2KDM1BCYP1A2CYP2D6 | |
| SCHEMBL3368263 | 0.77 | KDM4E (0.39) | PTPRCPTPN1ENPP2CYP11B1CYP11B2 | |
| SCHEMBL16922694 | 0.76 | KDM1A (0.39) | CYP11B1CYP11B2KDM4EKDM1AKCNH2 | |
| SCHEMBL24108188 | 0.76 | CYP11B1 (0.58) | ENPP2CYP11B1CYP11B2KCNH2 | |
| SCHEMBL8528308 | 0.76 | TRPV4 (0.39) | PTPRCPTPN1ENPP2CYP11B1CYP11B2 | |
| SCHEMBL192429 | 0.76 | MAPT (0.38) | PTPRCPTPN1ENPP2CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 195 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021042411-A1 | AKR1C3 INHIBITOR OR PHARMACEUTICALLY ACCEPTABLE SALT OF SAME, PREPARATION METHOD FOR SAME, AND USES THEREOF | 中国药科大学 | 2021-03-11 | — | — | WO | claimed |
| CN-110590548-A | AKR1C3 inhibitor or pharmaceutically acceptable salt thereof, preparation method and application thereof | 中国药科大学 | 2019-12-20 | — | — | CN | claimed |
| EP-4743453-A1 | MODULATORS OF MITOCHONDRIAL DNA REPLICATION | Pretzel Therapeutics, Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| US-12404283-B2 | c-MYC mRNA translation modulators and uses thereof in the treatment of cancer | ANIMA BIOTECH INC. (US) | 2025-09-02 | — | — | US | disclosed |
| CN-115151553-B | Boric acid derivatives | 首药控股(北京)股份有限公司 | 2025-06-13 | — | — | CN | disclosed |
| EP-4547672-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | Anima Biotech Inc. (US) | 2025-05-07 | — | — | EP | disclosed |
| US-20250129100-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | ANIMA BIOTECH INC. (US) | 2025-04-24 | — | — | US | disclosed |
| WO-2025080986-A1 | AMIDE COMPOUNDS | QUANTX BIOSCIENCES US, INC. (US) | 2025-04-17 | — | — | WO | disclosed |
| US-20250115608-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS | ARDELYX, INC. (US) | 2025-04-10 | — | — | US | disclosed |
| EP-3145915-B1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME LLC (US) | 2025-03-19 | — | — | EP | disclosed |
| US-20250042883-A1 | GLP-1R AGONISTS AND USES THEREOF | QILU REGOR THERAPEUTICS INC. (CN) | 2025-02-06 | — | — | US | disclosed |
| WO-2006133559-A1 | REVERSIBLE INHIBITORS OF MONOAMINE OXIDASE A AND B | MERCK FROSST CANADA LTD. (CA) | 2006-12-21 | — | — | WO | disclosed |
| EP-1694647-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | Merck Frosst Canada Ltd. (CA) | 2006-08-30 | — | — | EP | disclosed |
| US-20060063937-A1 | Geminallyl di-substituted nsaid derivatives as abeta 42 lowering agents | MERCK SHARP & DOHME CORP. | 2006-03-23 | — | — | US | disclosed |
| CN-1751018-A | 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases | CHIESI FARMA SPA (IT) | 2006-03-22 | — | — | CN | disclosed |
| EP-1594833-A1 | 1-PHENYLALKANECARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | CHIESI FARMACEUTICI S.p.A. (IT) | 2005-11-16 | — | — | EP | disclosed |
| EP-1587798-A2 | GEMINALLY DI-SUBSTITUTED NSAID DERIVATIVES AS ABETA 42 LOWERING AGENTS | Merck & Co., Inc. (US) | 2005-10-26 | — | — | EP | disclosed |
| WO-2005056529-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2005-06-23 | — | — | WO | disclosed |
| WO-2004074232-A1 | 1-PHENYLALKANECARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | CHIESI FARMACEUTICI S.P.A. (IT) | 2004-09-02 | — | — | WO | disclosed |
| WO-2004064771-A2 | GEMINALLY DI-SUBSTITUTED NSAID DERIVATIVES AS ABETA 42 LOWERING AGENTS | MERCK & CO., INC. (US) | 2004-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250129100-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | MYC, MYCBP, MYCBP2 | PTPRC 1394/4885PTPN1 3379/4885ENPP2 3656/4885 |
| US-20060063937-A1 | Geminallyl di-substituted nsaid derivatives as abeta 42 lowering agents | APP, PSEN1, CA1 | PTPRC 3894/4885PTPN1 4572/4885ENPP2 267/4885 |
| US-12404283-B2 | c-MYC mRNA translation modulators and uses thereof in the treatment of cancer | MYC, MYCBP, MYCBP2 | PTPRC 1394/4885PTPN1 3379/4885ENPP2 3656/4885 |
| US-20250042883-A1 | GLP-1R AGONISTS AND USES THEREOF | GLP1R, GPR119, GIPR | PTPRC 3474/4885PTPN1 1248/4885ENPP2 439/4885 |
| US-20250115608-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS | NR1H4, FXR1, GLP1R | PTPRC 1134/4885PTPN1 815/4885ENPP2 160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.